["{\n\"step_by_step_thinking\": \"The question asks which of the following is true about carbamazepine. The relevant documents mention no information about agranulocytosis or nephrogenic toxicity, but they do mention that vigilant follow-up is advised to avoid hematotoxic complications. No specific information about Steven-Johnson's syndrome is provided. Finally, the study on serum levels and suggested therapeutic range implies that drug monitoring may be necessary. Therefore, only option B can be supported by the available evidence.\",\n\"answer_choice\": \"B\"\n}"]